ProKidney Corp. (PROK NASDAQ) stock market data APIs
$2.5868
-0.14(-5.4%)
as of December 4, 2025
Try our APIs with
free plan!
ProKidney Corp. Financial Data Overview
Price chart is built with
Anychart
ProKidney Corp., a clinical-stage biotechnology company, develops a cell therapy platform for the treatment of multiple chronic kidney diseases in the United States. Its lead product candidate, rilparencel, includes autologous selected renal cells (SRC) in Phase 3 and Phase 2 clinical studies in subjects with moderate to severe chronic kidney disease and diabetes. The company also develops a cryopreserved version of rilparencel that allows for long-term product preservation to be used in Phase 2 and 3 trials of rilparencel. ProKidney Corp. was founded in 2015 and is headquartered in Winston-Salem, North Carolina.
Prev. Close
2.5868
Open
2.4508
High
2.6089
Low
2.4131
52 wk Range
0.4603-5.95
Market Cap
773 M
Shares Outstanding
142 M
Revenue
744 K
EPS
-0.12
Beta
1.797
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get ProKidney Corp. data using free add-ons & libraries
Get ProKidney Corp. Fundamental Data
ProKidney Corp. Fundamental data includes:
- Net Revenue: 744 K
- EBITDA: -164 576 992
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-11-10
- EPS/Forecast: -0.1461
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
ProKidney Corp. News
New
Promising Penny Stocks To Watch In December 2025
As the U.S. stock market experiences a slight uptick following a break in its recent winning streak, investors are closely monitoring the tech and crypto sectors for signs of rebound. Penny stocks, th...
While insiders own 18% of ProKidney Corp. (NASDAQ:PROK), retail investors are its largest shareholders with 50% ownership
Key Insights ProKidney's significant retail investors ownership suggests that the key decisions are influenced by shareholders from the larger public A total of 25 investors have a majority stake in ...
ProKidney Reports Third Quarter 2025 Financial Results and Provides Regulatory and Clinical Updates
Full results from the Phase 2 REGEN-007 study of rilparencel were recently presented as a late-breaking clinical trial at the American Society of Nephrology (ASN) Kidney Week 2025More than half of the...
ProKidney Reports Third Quarter 2025 Financial Results and Provides Regulatory and Clinical Updates
ProKidney Full results from the Phase 2 REGEN-007 study of rilparencel were recently presented as a late-breaking clinical trial at the American Society of Nephrology (ASN) Kidney Week 2025 More than...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
